Genentech To Resubmit Avastin sBLA In Mid-2007
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.